RenovoRx Inc. (RNXT)
0.98
-0.02 (-1.99%)
At close: Feb 28, 2025, 3:59 PM
1.00
1.93%
After-hours: Feb 28, 2025, 04:00 PM EST
Company Description
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors.
Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer.
RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.
RenovoRx Inc.
| Country | United States |
| IPO Date | Aug 26, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 8 |
| CEO | Shaun R. Bagai |
Contact Details
Address: 4546 El Camino Real Los Altos, California United States | |
| Website | https://renovorx.com |
Stock Details
| Ticker Symbol | RNXT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001574094 |
| CUSIP Number | 75989R107 |
| ISIN Number | US75989R1077 |
| Employer ID | 27-1448452 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Shaun R. Bagai | Chief Executive Officer, Secretary & Director |
| Dr. Ramtin Agah M.D. | Founder, Chairman of Board & Chief Medical Officer |
| Leesa Gentry | Chief Clinical Officer |
| Robert Strasser | Vice President of Operations and R&D |
| Ronald B. Kocak CPA, CGMA | Vice President, Controller & Principal Accounting Officer |
| Ryan Witt | Senior Vice President and Head of Corporate Strategy & Partnerships |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 10, 2025 | 8-K | Current Report |
| Feb 10, 2025 | 424B5 | Filing |
| Feb 06, 2025 | 424B5 | Filing |
| Nov 14, 2024 | 8-K | Current Report |
| Nov 13, 2024 | 10-Q | Quarterly Report |
| Oct 02, 2024 | 4 | Filing |
| Oct 02, 2024 | 4 | Filing |
| Oct 02, 2024 | 4 | Filing |
| Oct 02, 2024 | 4 | Filing |
| Sep 25, 2024 | 8-K | Current Report |